



## **Genzyme update on supply of Thyrogen® (thyrotropin alfa for injection)**

July 13, 2011

Genzyme would like to provide an update on Thyrogen availability. In the United States, intermittent shipments of the product resumed the week of June 20<sup>th</sup>. Outside of the United States, shipments were anticipated to resume in July. However, due to unexpected delays in the release of three “lots” (or batches of Thyrogen) intended for both U.S. and global distribution, Genzyme now expects to stock-out of Thyrogen in the U.S. in late-July. Outside of the U.S., current stock-outs are expected to persist until these lots are released.

The manufacturing of Thyrogen and the subsequent process to release the product for shipment are complex processes, and require months to complete. Since Genzyme has extremely limited inventory, even minor changes to our current manufacturing plan impact the timing of Thyrogen availability. This makes it difficult to predict when we will have product available for distribution.

Genzyme is uncertain as to the timing of when the three pending lots are going to be released, therefore the company is now advising health care providers not to schedule any new Thyrogen treatments until we can confirm that new lots of Thyrogen are available for distribution. For health care providers with patients currently scheduled to receive Thyrogen, but who have not secured product, Genzyme staff in each country will be able to provide more specific details on the current status of Thyrogen availability.

In addition, temporary shipment delays and regional disparities in supply availability are expected to continue to occur for the remainder of 2011 and throughout 2012. This is due to a combination of factors, including: ongoing Thyrogen manufacturing capacity constraints; longer timelines to manufacture and release Thyrogen into the market; a lack of inventory of the product; and an increase in global demand for Thyrogen. To address this, Genzyme is working to increase Thyrogen manufacturing capacity, and decrease lot release timelines.

Genzyme remains committed to Thyrogen. We are focused on restoring supply of the product and will continue to provide updates going forward. We sincerely regret the impact the supply constraints have had on the thyroid cancer community.